Influence of hepatic and renal disorders on the pharmacokinetics of sulfachloropyridacine.
The pharmacokinetics of sulfachloropyridacine were studied in a series of 30 adult patients (healthy volunteers, patients with moderate hepatic impairment and patients with renal impairment). In all cases a 500 mg dose of sodium sulfachloropyridacine was administered orally. The drug follows a single compartment pharmacokinetic model. In healthy patients the following pharmacokinetic parameters were established: Ka = 5.130 h-1, Ke = 0.205 h-1, tmax = 40 min, Vd = 7.94 liters, and in patients diagnosed with cirrhosis a decrease is appreciable in the absorption constant and in the area below the blood-time levels curve. A linear relationship is established between the elimination constant and creatinine clearance. A dosage regimen, applicable to patients with renal impairment, is established as a function of the pharmacokinetic parameters. The degree of plasma protein binding of sulfachloropyridacine diminishes significantly in patients with renal impairment.
D001798:Blood Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D011485:Protein Binding; D013410:Sulfachlorpyridazine / Q000097:blood / Q000378:metabolism*; D013424:Sulfanilamides / Q000378:metabolism*; D014511:Uremia / Q000378:metabolism
D001798:Blood Proteins; D013424:Sulfanilamides; D013410:Sulfachlorpyridazine